Skip to search formSkip to main contentSkip to account menu

0.8 ML adalimumab 50 MG/ML Injection [Humira]

Known as: 0.8 ML Humira 40 MG Injection, ADALIMUMAB 40 mg in 0.8 mL SUBCUTANEOUS INJECTION, SOLUTION [Humira], 0.8 ML Humira 50 MG/ML Injection 
National Institutes of Health

Related topics

Related topics

11 relations
HumiraInjectionMannitolPolysorbate 80

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
Quality by design (QbD) is an efficient but challenging approach for the development of biosimilar due to the complex… 
2020
2020
Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
Quality by design (QbD) is an efficient but challenging approach for the development of biosimilar due to the complex… 
2019
2019
Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira®.
2017
2017
Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development
The management of chronic inflammatory diseases, such as inflammatory bowel disease, psoriasis, and rheumatoid arthritis has… 
2016
2016
Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
ABSTRACT Biosimilars are biological products that are highly similar to existing products approved by health authorities… 
2014
2014
AB0412 Preclinical PK and Safety Assessment of the Proposed Adalimumab Biosimilar Gp2017, Compared to Humira®
Background TNFα inhibitors are highly effective drugs for the treatment of inflammatory disorders such as rheumatoid arthritis… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)